B-cell non-Hodgkin lymphoma
Therapeutic area
Hematology
Rare disease
Yes
- Definition
- The most common type of non-Hodgkin lymphoma. It includes the most frequently seen morphologic variants which are: diffuse large B-cell lymphoma, follicular lymphoma, small lymphocytic lymphoma and marginal zone B-cell lymphoma. -- 2003
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- B-cell non-Hodgkin lymphoma
- Therapeutic area
- Hematology
- B-cell non-Hodgkin lymphoma
- B-cell NHL
- B-cell lymphoma
- B-cell non Hodgkin's lymphoma
- B-cell non-Hodgkin lymphoma
- B-cell non-Hodgkin's lymphoma
- lymphomas non-Hodgkin's B-cell
- non-Hodgkin's B-cell lymphoma
- non-Hodgkin's lymphoma B-cell
- Severity
- Severe
- Hematology
- Immunology
- Oncology
- MONDO ID
- MONDO:0015759
- Parent condition
- MONDO:0004095
Related records
Broader conditions (17)
- B-cell neoplasm
- Cancer or benign tumor
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Hematologic disorder
- Hematopoietic and lymphoid cell neoplasm
- Hematopoietic and lymphoid system neoplasm
- Human disease
- Immune system disorder
- Leukocyte disorder
- Lymphoid hemopathy
- Lymphoid neoplasm
- Lymphoma
- Neoplasm
- Neoplastic disease or syndrome
- Non-Hodgkin lymphoma
Narrower conditions (96)
- A53 diffuse large B-cell lymphoma
- Aggressive B-cell non-Hodgkin lymphoma
- ALK-positive large B-cell lymphoma
- B acute lymphoblastic leukemia with DUX4 rearrangement
- B acute lymphoblastic leukemia with PAX5 P80R mutation
- B-cell acute lymphoblastic leukemia
- B-cell acute lymphoblastic leukemia with t(1;19)(q23;p13.3); E2A-PBX1 (TCF3-PBX1)
- B-cell adult acute lymphocytic leukemia
- B-cell childhood acute lymphoblastic leukemia
- B-cell chronic lymphocytic leukemia
- B-cell prolymphocytic leukemia
- B-lymphoblastic leukemia with MEF2D rearrangement
- B-lymphoblastic leukemia with MYC rearrangement
- B-lymphoblastic leukemia with NUTM1 rearrangement
- B-lymphoblastic leukemia with PAX5alt
- B-lymphoblastic leukemia with TCF3-HLF fusion
- B-lymphoblastic leukemia with ZNF384 rearrangement
- B-lymphoblastic leukemia/lymphoma MLL rearranged
- B-lymphoblastic leukemia/lymphoma with ETV6-RUNX1
- B-lymphoblastic leukemia/lymphoma with IAMP21
Trials (498)
- 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation
- a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma
- A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies
- A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in Childhood R/R ALL and Lymphoma Subjects
- A Clinical Study Evaluating the Safety and Efficacy of BinD19 Treatment in R/R ALL and Lymphoma Subjects
- A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia
- A Clinical Study Exploring CT1190B in the Treatment of Patients with Relapsed/refractory B-cell Non-Hodgkin Lymphoma
- A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG11001 )
- A Clinical Study Exploring CT1190B in the Treatment of Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma ( CT1190B-CG1101 )
- A Clinical Study Exploring CT1194C in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
- A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors
- A Clinical Study of CAR-T Cells Treatment for Children With CD19+/CD22+ R/R ALL and Lymphoma
- A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia
- A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide
- A Clinical Study of of RN1701 Injection in the Treatment of Relapsed/Refractory B-Cell Lymphomas
- A Clinical Study of SHR-3079 in B-cell Non-Hodgkin Lymphoma
- A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma
- A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms
- A Cognitive Training Intervention for Improving Cognitive and Neurological Outcomes in Patients Undergoing Treatment for Relapsed or Refractory Multiple Myeloma or B-cell Non-Hodgkin Lymphoma
Approved drugs (2)
Drugs in development (51)
- AFM-11 Phase 1
- APL-501 Phase 2
- Bendamustine Phase 1
- Bezetabart debotansine Phase 1
- Bortezomib Phase 2
- Carboplatin Phase 2
- Cerdulatinib Phase 2
- CPI 613 Phase 2
- CPI-1205 Phase 1
- Cyclophosphamide Phase 2
- Doxorubicin Phase 1
- Doxorubicin hydrochloride Phase 2
- Duvortuxizumab Phase 1
- Entospletinib Phase 2
- Epcoritamab Phase 1
- Epratuzumab 90Y Phase 1
- Fludarabine Phase 1
- Glofitamab Phase 2
- Ibrutinib Phase 3
- Ifosfamide Phase 2
Other linked drugs (9)
- Allantoin
- Bendamustine hydrochloride
- BI-1206
- DI-LEU16-IL2
- Emzadirib
- Magrolimab
- Nelitolimod
- Orelabrutinib
- Vecabrutinib